Mitigating Cardiovascular Risk Through Effective Lipid Management

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

An expert advises how to optimize the care continuum for patients with ASCVD.

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.

Dr Brinton highlights the importance of adjunct therapies in LDL management.

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.

Drs Riddock and Slipczuk define “optimal care” for ASCVD from a system-level perspective with the use of quality metrics.

Drs Brinton and Slipczuk go into detail regarding an ideal multidisciplinary team for ASCVD treatment.

Three cardiovascular experts discuss the future of lipid management for patients with high-risk ASCVD.

Dr Leandro N. Slipczuk highlights the importance of cardiovascular treatment guidelines when deciding on patient care for those with ASCVD.

Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.

Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.